Cite
HARVARD Citation
Vernieri, F. et al. (2022). Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study. European journal of neurology. pp. 1198-1208. [Online].